Plasminogen activator inhibitor-1 and thrombin activable fibrinolysis inhibitor in patients with type 2 diabetes

被引：0
|
作者：
Blaszkowski, A. [1 ]
Galar, M. [1 ]
Sokolowski, J. [1 ]
Kloczko, J. [1 ]
机构：
[1] Med Univ Bialystok, Bialystok, Poland
来源：
DIABETOLOGIA | 2010年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1329
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Bispecific targeting of thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 by a heterodimer diabody
    Develter, J.
    Booth, N. A.
    Declerck, P. J.
    Gils, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (11) : 1884 - 1891
  • [2] Fibrinolysis and diabetic vascular disease: roles of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor
    Aso, Yoshimasa
    FUTURE LIPIDOLOGY, 2006, 1 (04): : 429 - 440
  • [3] Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis
    S. Yener
    M. Akarsu
    T. Demir
    B. Akinci
    O. Sagol
    F. Bayraktar
    M. A. Ozcan
    E. Tankurt
    S. Yesil
    Journal of Endocrinological Investigation, 2007, 30 : 810 - 819
  • [4] Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis
    Yener, S.
    Akarsu, M.
    Demir, T.
    Akinci, B.
    Sagol, O.
    Bayraktar, F.
    Ozcan, M. A.
    Tankurt, E.
    Yesil, S.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2007, 30 (10) : 810 - 819
  • [5] Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients
    Kitagawa, Nagako
    Yano, Yutaka
    Gabazza, Esteban C.
    Bruno, Nelson E.
    Araki, Rika
    Matsumoto, Kazutaka
    Katsuki, Akira
    Hori, Yasuko
    Nakatani, Kaname
    Taguchi, Osamu
    Sumida, Yasuhiro
    Suzuki, Koji
    Adachi, Yukihiko
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2006, 73 (02) : 150 - 157
  • [6] Thrombin Activable Fibrinolysis Inhibitor
    徐成伟
    血栓与止血学, 2009, 15 (03) : 99 - 100
  • [7] Plasminogen activator inhibitor-1 is increased in type 1 diabetes patients with hypertension
    Zheng, DY
    Hunter, SJ
    Lackland, DT
    Garvey, WT
    Klein, RL
    DIABETES, 1999, 48 : A43 - A43
  • [8] Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes - Synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor
    Aso, Y
    Wakabayashi, S
    Yamamoto, R
    Matsutomo, R
    Takebayashi, K
    Inukai, T
    DIABETES CARE, 2005, 28 (09) : 2211 - 2216
  • [9] Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease
    Koutroubakis, Ioannis E.
    Sfiridaki, Aekaterini
    Tsiolakidou, Georgia
    Coucoutsi, Constantina
    Theodoropoulou, Angeliki
    Kouroumalis, Elias A.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2008, 20 (09) : 912 - 916
  • [10] Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients
    Akinci, Barls
    Comlekci, Abdurrahman
    Yener, Serkan
    Demir, Tevfik
    Ozcan, Mehmet Ali
    Bayraktar, Firat
    Yesil, Sena
    ENDOCRINE JOURNAL, 2007, 54 (04) : 593 - 599
12345